Literature DB >> 11181881

Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate.

A Windhagen, S Maniak, S Marckmann, R B Lindert, F Heidenreich, R Blasczyk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11181881      PMCID： PMC1737279          DOI： 10.1136/jnnp.70.3.415

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  4 in total

1.  Glatiramer acetate persists at the injection site and draining lymph nodes via electrostatically-induced aggregation.

Authors:  Jimmy Y Song; Nicholas R Larson; Sharadvi Thati; Irma Torres-Vazquez; Noraida Martinez-Rivera; Natalia J Subelzu; Martin A Leon; Eduardo Rosa-Molinar; Christian Schöneich; M Laird Forrest; C Russell Middaugh; Cory J Berkland
Journal:  J Control Release       Date:  2018-11-07       Impact factor: 9.776

2.  Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Authors:  T Ziemssen; O Neuhaus; R Hohlfeld
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

Authors:  Dene Simpson; Stuart Noble; Caroline Perry
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis.

Authors:  E Wiesemann; J Klatt; C Wenzel; F Heidenreich; A Windhagen
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.